Lyell Immunopharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	632	489	865	1,861	-	-
Market Cap Growth	-	-43.52%	-53.52%	-	-	-
Enterprise Value	170	-1	288	1,313	-562	-411
PE Ratio	-2.48	-2.08	-4.72	-7.44	-	-
PS Ratio	9428.92	3758.66	10.22	174.77	-	-
PB Ratio	1.06	0.75	1.04	2.00	-	-
P/FCF Ratio	-3.53	-2.94	-4.46	-9.71	-	-
P/OCF Ratio	-3.55	-2.98	-5.10	-14.74	-	-
EV/Sales Ratio	2496.17	-7.59	3.40	123.25	-72.48	-625.15
EV/EBITDA Ratio	-0.46	0.00	-1.74	-5.55	2.81	3.21
EV/EBIT Ratio	-0.42	0.00	-1.57	-5.25	2.75	3.17
EV/FCF Ratio	-0.59	0.01	-1.49	-6.85	2.65	-17.53
Debt / Equity Ratio	0.09	0.09	0.08	0.07	-0.17	-0.24
Debt / EBITDA Ratio	-0.27	-0.27	-0.38	-0.28	-0.25	-0.21
Debt / FCF Ratio	-0.34	-0.34	-0.33	-0.35	-0.24	1.16
Quick Ratio	16.28	15.83	17.30	13.16	12.44	19.86
Current Ratio	16.51	16.07	17.59	13.40	12.53	19.97
Asset Turnover	0	0	0.09	0.01	0.01	-
Return on Equity (ROE)	-33.90%	-32.70%	-21.50%	-38.40%	103.10%	-
Return on Assets (ROA)	-29.70%	-28.80%	-18.30%	-22.60%	-28.40%	-
Return on Capital (ROIC)	-36.46%	-34.70%	-20.87%	-21.55%	87.73%	121.56%
Earnings Yield	-35.61%	-48.02%	-21.17%	-13.44%	-	-
FCF Yield	-25.06%	-34.05%	-22.40%	-10.30%	-	-
Buyback Yield / Dilution	-1.87%	-1.58%	-81.79%	-925.18%	-144.21%	-
Total Shareholder Return	-1.87%	-1.58%	-81.79%	-925.18%	-144.21%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).